Type-specific antigens for serological discrimination of HTLV-I and HTLV-II infection

Chen, Y.A.; Lee, T.-H.; Essex, Max; Wiktor, Stefan Z.; Blattner, William A.; Shaw, GM; Murphy, Edward L.

doi:10.1016/0140-6736(90)92769-e

Cited by 33 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PCR HTLV-I1 sample was indeterminate by WB applying the WHO criteria, but with stronger reactivity to p24 than to p19. However, definitive differentiation can be done only by molecular techniques such as gene amplification (PCR) or using a serologic test (Chen et al, 1990) based on HTLV-I-and HTLV-IIspecific recombinant proteins. This study indicates that in Gabon HTLV-I infection is preponderant (12/13 HTLV-DNA-positive samples), but HTLV-I1 is also present.…”

Section: Discussionmentioning

confidence: 99%

“…The radioimmunoprecipitation Assay (RIPA) and polymerase chain reaction (PCR) appear to be better confirmatory tests, but they cannot be performed routinely as easily as a commercial Western blot. Another disadvantage of currently available serological tests is that they cannot make a reliable distinction between antibodies against HTLV-I and against HTLV-I1 (Cann and Chen, 1990), though specific serologic assays are currently under development (Chen et al, 1990). Unlike HTLV-I, HTLV-11, a closely related retrovirus, has not been formally linked with any disease and very little is known about its epidemiology.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of HTLV‐I and HTLV‐II infection in gabon, africa: Comparison of the serological and pcr results

Delaporte

Monplaisir²,

Louwagie

et al. 1991

Intl Journal of Cancer

View full text Add to dashboard Cite

A cluster sampling survey was performed in 1989 in Libreville, Gabon, to determine HTLV-I and HTLV-II prevalence and to compare the efficacy of polymerase chain reaction (PCR) and serology in detecting HTLV-I and HTLV-II infections. A total of 322 sera from adults were tested by ELISA and by Western blot (WB). The WB patterns were interpreted according to WHO criteria and those of the manufacturer. PCR analysis using primer pairs in the gag and pol region, with a specific probe for HTLV-I and HTLV-II, was performed on the lymphocytes of the 322 adults. In addition, 134/322 samples were re-tested with tax primers, in a second laboratory. Using WHO criteria, 8/322 (2.5%) samples were positive on WB and 25 were indeterminate; with the criteria of the kit, 26/322 (8.1%) were positive and 7 were indeterminate by WB. By PCR, 13 (4%) samples were positive, including 12 for HTLV-I (3.7%) and one for HTLV-II (0.3%). All 8 seropositive samples (by the WHO criteria) were positive by PCR, as were 4 out of 25 indeterminate samples. Only one out of 289 seronegative samples was positive by PCR. In contrast, only 12/26 positive samples by the kit criteria were confirmed by PCR. These results confirm the relatively high HTLV-I/II seroprevalence observed in Gabon. HTLV-I infection is preponderant, but HTLV-II is also present. The WHO criteria for WB give a better fit with PCR results than the kit criteria for WB. In the absence of a specific confirmatory test and based on the uncommon "seronegative" HTLV-I/II infection, the indication for PCR appears limited to the positive WB samples (to differentiate HTLV-I and II infection) and to the indeterminate WB samples.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Prevalence of HTLV‐I and HTLV‐II infection in gabon, africa: Comparison of the serological and pcr results

Delaporte

Monplaisir²,

Louwagie

et al. 1991

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Following our submission of this manuscript, Chen et al (34), using recombinant antigens in Western blot assays, identified major epitopes in the gp46 of HTLV-1 and HTLV-II. Although these assays could specifically detect HTLV-I antibody, they were relatively nonspecific for the detection of antibodies to HTLV-I1.…”

Section: Discussionmentioning

confidence: 99%

Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.

Horal

Hall

Svennerholm

et al. 1991

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Synthetic peptides of 20-25 amino acids were employed in enzyme-linked immunosorbent assays to identify linear epitopes in the external glycoprotein gp46 and the transmembrane glycoprotein gp2l of human T-cell leukemia/lymphotropic viruses type I (HTLV-I) and II (HTLV-II).Ten linear epitopes were identified in the HTLV-I glycoproteins, seven in gp46 and three in gp2l. Three major linear epitopes were identified in the gp46 of HTLV-II. Peptides representing linear epitopes of gp46 were found to be sensitive and specific for the detection of antibody and permit serological identification and differentiation of HTLV-I and HTLV-II infections.

show abstract

“…Commercial ELISA tests use, either alone or in combination, disrupted purified virions or specific peptides and recombinant proteins of HTLV-I or HTLV-II (Chen et al, 1990;LilIehoj et al, 1990;Lai et al, 1991;Washitani et al, 1991;Bonis et al, 1993;Rudolph et al, 1993Rudolph et al, , 1994LaI, 1996). The specificity and sensitivity of these assays have been defined (Kline et al, 1991;Wiktor et al, 1991;Cossen et al, 1992;KaropoIous et al, 1993;J ang et aL.…”

Section: Serological Detection Of Specifie Antibodiesmentioning

confidence: 99%

Monographs on the Evaluation of Carcinogenic Risks to Humans

1991

Analytica Chimica Acta

View full text Add to dashboard Cite

Type-specific antigens for serological discrimination of HTLV-I and HTLV-II infection

Cited by 33 publications

References 18 publications

Prevalence of HTLV‐I and HTLV‐II infection in gabon, africa: Comparison of the serological and pcr results

Prevalence of HTLV‐I and HTLV‐II infection in gabon, africa: Comparison of the serological and pcr results

Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.

Monographs on the Evaluation of Carcinogenic Risks to Humans

Contact Info

Product

Resources

About